A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
An open-label phase to assess the frequency and severity of adverse events in recurrent
glioblastoma patients receiving Sativex in combination with dose-intense Temozolomide (Part
A). A randomisation phase to assess the safety of Sativex compared with placebo (Part B).
Part B will be reported here.